FCRL2 mRNA expression is inversely associated with clinical progression in chronic lymphocytic leukemia

Eur J Haematol. 2009 Dec 1;83(6):541-9. doi: 10.1111/j.1600-0609.2009.01328.x. Epub 2009 Aug 4.

Abstract

Fc receptor-like 2 (FCRL2) is highly expressed on B-cell chronic lymphocytic leukemia (B-CLL) cells and could possibly influence disease pathogenesis. Therefore, we investigated FCRL2 mRNA expression in a large cohort with 152 CLL patients in order to assess its role in risk prediction in B-CLL. FCRL2 mRNA expression was found to be expressed at considerably higher levels in peripheral blood mononuclear cells (PBMC) of B-CLL patients compared to controls (range 1.35- to 210-fold upregulation; P < 0.0001) and cells of other hematological diseases. Patients with high FCRL2 expression (according to ROC-analysis) had a significantly longer treatment-free survival (TFS) and overall survival (OS) than patients with low FCRL2 expression (median TFS: 119 vs. 34 months, P < 0.0001; median OS: 321 months vs. not reached, P = 0.009). Univariate comparisons found that FCRL2 expression was weakly associated with IGHV mutation status (P = 0.05), CD38 status (P < 0.0001) and ZAP-70 status (P < 0.0001). Furthermore, we show that the combination of FCRL2 with ZAP70-, CD38- or IGHV-status could further significantly refine the prognostic information provided by either of the factors alone in TFS and OS. In multivariate analysis low FCRL2 expression was a significant independent prognostic factor (HR 2.4; P = 0.005). Here we demonstrate that the level of FCRL2 expression is correlated with prognosis in B-CLL.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADP-ribosyl Cyclase 1 / blood
  • Aged
  • Disease Progression
  • Disease-Free Survival
  • Female
  • Gene Expression Regulation, Leukemic
  • Hematologic Diseases / blood
  • Humans
  • Immunoglobulin Heavy Chains / genetics
  • Immunoglobulin Variable Region / genetics
  • Leukemia, Lymphocytic, Chronic, B-Cell / blood*
  • Leukemia, Lymphocytic, Chronic, B-Cell / mortality
  • Leukocytes, Mononuclear / chemistry
  • Male
  • Membrane Glycoproteins / blood
  • Middle Aged
  • Neoplasm Proteins / biosynthesis
  • Neoplasm Proteins / blood*
  • Neoplasm Proteins / genetics
  • Polymorphism, Single Nucleotide
  • Prognosis
  • RNA, Messenger / blood
  • RNA, Neoplasm / blood
  • ROC Curve
  • Receptors, Cell Surface / biosynthesis
  • Receptors, Cell Surface / blood*
  • Receptors, Cell Surface / genetics
  • Retrospective Studies
  • Survival Analysis
  • ZAP-70 Protein-Tyrosine Kinase / blood

Substances

  • FCRL2 protein, human
  • Immunoglobulin Heavy Chains
  • Immunoglobulin Variable Region
  • Membrane Glycoproteins
  • Neoplasm Proteins
  • RNA, Messenger
  • RNA, Neoplasm
  • Receptors, Cell Surface
  • ZAP-70 Protein-Tyrosine Kinase
  • ZAP70 protein, human
  • CD38 protein, human
  • ADP-ribosyl Cyclase 1